Rare diseases focused Mereo BioPharma said it had agreed to raise up to $33m from Novartis and investment group Aspire Capital Fund. Novartis had entered into a $5m convertible equity financing arrangement with the company. Aspire Capital Fund, meanwhile, would be issued up to $28m of the company's ordinary shares exchangeable for American Depositary Shares, including a $3m initial purchase. Proceeds from the transactions would be used for general corporate purposes, including clinical trial activity and working capital. At 2:00pm: (LON:MPH) Mereo Biopharma Group Ltd share price was +4.5p at 29.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.